
New research reveals that the gut microbial metabolite imidazole propionate (ImP) is linked to coronary artery disease by impairing endothelial cell repair and promoting inflammation. Human and animal studies show ImP worsens atherosclerosis by disrupting insulin signaling. Targeting ImP metabolism could offer a novel approach to treating cardiovascular disease.
Like
Save
Share